• Molecular NameBiperiden
  • SynonymBeperiden; Biperiden [Usan:Ban:Inn:Jan]; Biperiden Hydrochloride; Biperidene [INN-French]; Biperidene Hydrochloride; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperidine; Biperidine Hydrochloride
  • Weight311.469
  • Drugbank_IDDB00810
  • ACS_NO514-65-8
  • Show 3D model
  • LogP (experiment)4.25
  • LogP (predicted, AB/LogP v2.0)4.13
  • pkaN/A
  • LogD (pH=7, predicted)1.76
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.65
  • LogSw (predicted, AB/LogsW2.0)0.28
  • Sw (mg/ml) (predicted, ACD/Labs)0.06
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds5
  • TPSA23.47
  • StatusFDA approved
  • AdministrationOral, IM, IV
  • PharmacologyAn antiparkinsonian agent of the anticholinergic type.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability30.0
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic hydroxylation
  • Half life18 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • Clerance146 L/h (oral).
  • ToxicityFor a summary of fatalities caused by anticholinergics in Norway, see P. Gjerden et al.,Tidsskr Nor Laegeforen,1998, 118, 42–44.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A